The PharmNovo Journey

Guaranteed through Phase IIA PoC studies

HAVING FINALISED pre-clinical studies for PN6047, current focus is on taking this lead compound through regulatory toxicology and first in man trials. Our aim is to establish efficacy through Phase IIA PoC studies in one or more patient populations starting in 2023.

Prior to 2020

Establishing the base

Founding PharmNovo
PN6047 discovered
Convincing pre-clinical efficacy data
Patent applications in major markets

→

2020-2023

Setting the scene

GMP compound production and process development
Toxicology studies to support clinical studies
Phase I and clinical target engagement studies
Secure patent protection in all major markets

→

2023 -

Launch

Establishing efficacy and defining path to market
Phase IIA PoC efficacy studies in one or more patient populations
Identification of VC/Pharma partner
Alignment of path to market with regulatory authorities, in particular EMA and FDA

Latest news

View all

December 22, 2022

PharmNovo at Biostock

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.

December 22, 2022

Seasons Greetings 2022

The PharmNovo team would like to wish you a Merry Christmas and a Happy New Year!

October 11, 2022

Strengthening the team

PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager

September 20, 2022

Good press in SvD

Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

FIRST IN MAN TRIALS